Compare Recursion Pharmaceuticals Inc (RXRX) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs First Trust Cloud Computing ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B), while First Trust Cloud Computing ETF trades at $161.37. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SKYY | |
|---|---|---|
Market Cap | $1.81B | — |
Sector | Health | — |
52-Week High | $6.79 | $161.09 |
52-Week Low | $2.84 | $104.16 |
Enterprise Value | $1.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
First Trust Cloud Computing ETF (SKYY) trades at $163.00, up 1.38% with bullish technical signals from moving averages and ADX indicators. The ETF provides diversified exposure to cloud infrastructure, software, and AI companies, benefiting from secular trends in cloud migration and AI adoption. Recent news highlights strong institutional interest in technology ETFs and SKYY's positioning in the expanding AI ecosystem beyond semiconductors.
SKYY offers exposure to cloud computing growth drivers with technical momentum supporting near-term upside. Key risks include technology sector volatility and competitive pressures from global cloud initiatives. The ETF's diversified approach mitigates concentration risk while capturing broader technology transformation trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
